Myocarditis and myopericarditis cases following COVID-19 mRNA vaccines administered to 12-17-year olds in Victoria, Australia.

Daryl R ChengHazel J ClothierHannah J MorganEmma RoneyPriya ShentonNicholas CoxBryn O JonesSilja SchraderNigel W CrawfordJim P Butterynull null

Published in: BMJ paediatrics open (2022)

Accurate evaluation and confirmation of episodes of COVID-19 mRNA vaccine-associated myocarditis enabled understanding of clinical phenotypes in the adolescent age group. Any potential vaccination and safety surveillance policies needs to consider age and gender differences.

Keyphrases

coronavirus disease
sars cov
public health
young adults
respiratory syndrome coronavirus
binding protein
high resolution
climate change